HUTCHMED: all 118 studies

Page 1 of 2. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.

• HMPL-A830 in Solid TumorsRecruitingNCT07718581Phase 1/2
• A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLRecruitingNCT07409428Phase 3
• HMPL-A580 in Participants With Advanced or Metastatic Solid TumorRecruitingNCT07396584Phase 1/2
• A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid TumorsRecruitingNCT07228247Phase 1/2
• Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 MutationsRecruitingNCT07025018Phase 1
• Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial CancerRecruitingNCT06584032Phase 3
• A Clinical Study of HMPL-506 in Patients With Hematological MalignanciesRecruitingNCT06387082Phase 1
• A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid LeukemiaRecruitingNCT06387069Phase 3
• A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic CancerRecruitingNCT06361888Phase 2/3
• A Study of HMPL-415S1 in Patients With Advanced Malignant Solid TumorsRecruitingNCT05886374Phase 1
• A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine CarcinomaRecruitingNCT05015621Phase 3
• HMPL-453 Tartrate in Advanced Intrahepatic CholangiocarcinomaRecruitingNCT04353375Phase 2/3
• A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid TumorsCompletedNCT05093322Phase 1/2Results posted
• A Study of HMPL-306 in Advanced Hematological Malignancies With mIDHTerminatedNCT04764474Phase 1Results posted
• A Study of HMPL-306 in Advanced Solid Tumors With IDH MutationsTerminatedNCT04762602Phase 1Results posted
• Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsTerminatedNCT04579757Phase 1/2Results posted
• Open-Label Surufatinib in European Patients With NETTerminatedNCT04579679Phase 2Results posted
• A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid TumorsTerminatedNCT04577963Phase 1/2Results posted
• A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal CancerCompletedNCT04322539Phase 3Results posted
• Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With LymphomasTerminatedNCT03786926Phase 1Results posted
• An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With LymphomaTerminatedNCT03779113Phase 1Results posted
• A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast CancersCompletedNCT03251378Phase 1Results posted
• A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid TumorsCompletedNCT02549937Phase 1/2Results posted
• Study of Fruquintinib in Patients With Metastatic Colorectal CancerCompletedNCT02196688Phase 2Results posted
• HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative ColitisTerminatedNCT01882764Phase 3Results posted
• A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative ColitisTerminatedNCT01805791Phase 3Results posted
• Phase II Study of HMPL-004 in Patients With Ulcerative ColitisCompletedNCT00659802Phase 2Results posted
• Phase II Study of HMPL-004 in Subjects With Crohn's DiseaseCompletedNCT00655733Phase 2Results posted
• The Study on Effects of CYP3A and P-glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampin of HMPL-453 Tartrate TabletsCompletedNCT07697157Phase 1
• Study on [14C]HMPL-453（FGFR Inhibitor） in Healthy Chinese Adult Male SubjectsCompletedNCT07644442Phase 1
• A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 CapsulesCompletedNCT07643272Phase 1
• Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate TabletsCompletedNCT07348133Phase 1
• Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in HumansCompletedNCT07331194Phase 1
• Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male SubjectsCompletedNCT06671873Phase 1
• Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCLCompletedNCT06601504Phase 2
• The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)WithdrawnNCT06291415Phase 1
• HMPL-453 Food Effect and PPI Study in Healthy Volunteer StudyCompletedNCT05930119Phase 1
• Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese SubjectsCompletedNCT05781906Phase 1
• HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer StudyCompletedNCT05720767Phase 1
• A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory LymphomaCompletedNCT05713110Phase 2
• HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPICompletedNCT05602597Phase 1
• HMPL-523 Food Effect and Proton Pump Inhibitor StudyCompletedNCT05571787Phase 1
• HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaActive, not recruitingNCT05535933Phase 2/3
• Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)CompletedNCT05522231Phase 2/3
• Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung CancerCompletedNCT05509699Phase 2
• Tazemetostat for the Treatment of Relapsed/Refractory Follicular LymphomaCompletedNCT05467943Phase 2
• A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant NeoplasmCompletedNCT05429008Phase 1
• Fruquintinib DDI Study With P-gp and BCRP SubstratesCompletedNCT05368805Phase 1
• A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different ManufacturersCompletedNCT05318820Early Phase 1
• Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCTStatus unknownNCT05277454Phase 1
• Fruquintinib Hepatic Impairment StudyCompletedNCT05216367Phase 1
• Fruquintinib Renal Impairment StudyCompletedNCT05216354Phase 1
• HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT05190068Phase 1
• HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHLWithdrawnNCT05176691Phase 1
• A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid TumorsCompletedNCT05173142Phase 1/2
• Open-label Study of Surufatinib in Japanese PatientsCompletedNCT05077384Phase 1/2
• Phase III Study on HMPL-523 for Treatment of ITPCompletedNCT05029635Phase 3
• Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationCompletedNCT05015608Phase 3
• Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLCActive, not recruitingNCT05009836Phase 3
• Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PatientsCompletedNCT04923945Phase 3
• Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma PatientsCompletedNCT04923932Phase 2
• A Study of HMPL-295S1 in Patients With Advanced Malignant Solid TumorsCompletedNCT04908046Phase 1
• Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular LymphomaCompletedNCT04849351Phase 2
• Expanded Access Program of SurufatinibNo longer availableNCT04814732
• Surufatinib Renal Impairment StudyCompletedNCT04755088Phase 1
• Surufatinib Hepatic Impairment StudyCompletedNCT04755075Phase 1
• Fruquintinib Food Effect and Proton Pump Inhibitor StudyCompletedNCT04645940Phase 1
• Fruquintinib CYP3A Inhibitor and Inducer StudyCompletedNCT04557397Phase 1
• Surufatinib DDI With a PPI and a CYP3A InducerCompletedNCT04510649Phase 1
• A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy SubjectsCompletedNCT04372407Phase 1
• A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy SubjectsCompletedNCT04372394Phase 1
• HMPL-453 in Advanced Malignant MesotheliomaStatus unknownNCT04290325Phase 2
• A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/NeoplasmsStatus unknownNCT04272957Phase 1
• Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid TumorsCompletedNCT04169672Phase 2
• A Phase IV Study of Elunate® (Fruquintinib) in Chinese PatientsCompletedNCT04005066
• The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia PatientsCompletedNCT03951623Phase 1
• : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid TumorsCompletedNCT03903705Phase 1/2
• A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma PatientsStatus unknownNCT03873532Phase 2/3
• A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male VolunteersCompletedNCT03860948Phase 1
• Phase I Clinical Trial in Healthy Male VolunteersCompletedNCT03860532Phase 1
• Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLCWithdrawnNCT03684967Phase 2
• A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]SulfatinibCompletedNCT03627520Early Phase 1
• Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid LeukemiaTerminatedNCT03483948Phase 1
• To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different ManufacturersCompletedNCT03483259Phase 1
• HMPL-813 in Treating Patients With GlioblastomaStatus unknownNCT03231501Phase 1
• A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)CompletedNCT03223376Phase 3
• A Study of HMPL-453 in Patients With Advanced Solid MalignanciesStatus unknownNCT03160833Phase 1/2
• A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care ExistedCompletedNCT03128164Phase 1
• A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung CancerCompletedNCT02976116Phase 2
• Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract CarcinomaCompletedNCT02966821Phase 2
• A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid MalignanciesTerminatedNCT02966171Phase 1
• A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung CancerStatus unknownNCT02897479Phase 2
• A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell NeoplasmsCompletedNCT02857998Phase 1
• A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung CancerCompletedNCT02691299Phase 3
• A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] FruquintinibCompletedNCT02689752Phase 1
• A Study of HMPL-689 in Healthy VolunteersCompletedNCT02631642Phase 1
• Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid CarcinomaCompletedNCT02614495Phase 2
• Study of Theliatinib (HMPL-309) in Patients With Advanced Solid TumorTerminatedNCT02601274Phase 1
• Study of Theliatinib (HMPL-309) in Patients With Advanced Solid TumorCompletedNCT02601248Phase 1
• A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung CancerCompletedNCT02590965Phase 2

← HUTCHMED overview and focus areas